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GDF15 is an established biomarker of cellular stress.
The fact that it signals via a specific hindbrain recep-
tor, GFRAL, and that mice lacking GDF15 manifest
diet-induced obesity suggest that GDF15 may play
a physiological role in energy balance. We performed
experiments in humans, mice, and cells to determine
if and how nutritional perturbations modify GDF15
expression. Circulating GDF15 levels manifest very
modest changes in response tomoderate caloric sur-
pluses or deficits in mice or humans, differentiating
it from classical intestinally derived satiety hormones
and leptin. However, GDF15 levels do increase
following sustained high-fat feeding or dietary amino
acid imbalance in mice. We demonstrate that GDF15
expression is regulated by the integrated stress
response and is induced in selected tissues in mice
in these settings. Finally, we show that pharmacolog-
ical GDF15 administration to mice can trigger condi-
tioned taste aversion, suggesting that GDF15 may
induce an aversive response to nutritional stress.
INTRODUCTION
GDF15 (growth differentiation factor 15; also known as macro-
phage inhibitory cytokine-1 [MIC-1], NAG1, PLAB, and PDF) isCell Metabolism 29, 707–718, M
This is an open access article unda stress-induced cytokine and an atypical member of the trans-
forming growth factor beta superfamily (Tsai et al., 2016). Boot-
cov et al. originally characterized it as a dimeric protein secreted
by activated macrophages (Bootcov et al., 1997). In healthy an-
imals, it is predominantly expressed in the liver, lung, and kidney
and, at least in humans, in large amounts in the placenta (Bo¨tt-
ner et al., 1999; Ding et al., 2009; Fairlie et al., 1999; Lawton
et al., 1997; Marjono et al., 2003; Yokoyama-Kobayashi et al.,
1997). It circulates at high levels in humans (Brown et al.,
2003; Ho et al., 2012; Kempf et al., 2007; Mullican and Rang-
wala, 2018) and serum levels are known to increase with age,
smoking, intense exercise, cancer, and a range of other disease
states (reviewed in Corre et al., 2013; Kleinert et al., 2018;
Unsicker et al., 2013). It appears that almost any cell or tissue
can express GDF15 in response to various forms of stress
(Appierto et al., 2009; Chung et al., 2017; Hsiao et al., 2000;
Park et al., 2012; Yang et al., 2010). The measurement of circu-
lating concentrations of GDF15 is beginning to enter clinical
practice as a diagnostic biomarker in mitochondrial disease
and as a prognostic marker in conditions such as heart failure
and certain cancers (Fujita et al., 2016; Wang et al., 2013;
Wollert et al., 2017).
Johnen et al. first reported that mice bearing tumors engi-
neered to overexpress GDF15 lost weight dramatically (Johnen
et al., 2007). This could also be reproduced by injection of
recombinant GDF15 and prevented by a neutralizing GDF15
antibody. Transgenic GDF15-expressing mice similarly lost
weight secondary to reduced food intake (Chrysovergis et al.,
2014; Macia et al., 2012). Conversely, GDF15 null mice werearch 5, 2019 ª 2018 The Author(s). Published by Elsevier Inc. 707
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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reported to be slightly heavier (6%–10%) than their wild-type
littermates (Tsai et al., 2013) on a chow diet (CD), a difference
that becomes more striking on a high-fat diet (HFD) (Tran
et al., 2018). GDF15 injection induced cFos activation in
selected regions of the brainstem, particularly the nucleus trac-
tus solitarius (NTS) and area prostrema (AP). Selective lesioning
of these hindbrain regions rendered mice unresponsive to the
anorexigenic actions of GDF15 (Tsai et al., 2014). Recently, it
has been demonstrated that these effects of GDF15 are medi-
ated via a receptor composed of a heterodimer of Ret and a
member of the GDNF receptor alpha (GFRa) family, known as
GFRa-like or GFRAL (Emmerson et al., 2017; Hsu et al., 2017;
Mullican et al., 2017; Yang et al., 2017). Notably, GFRAL
expression appears to be strictly confined to the AP and NTS.
In addition to reporting the structure of GFRAL, these papers
also showed that GFRAL knockout (KO) mice are resistant to
the anorectic effects of exogenous injected GDF15 and to
endogenously secreted GDF15 levels induced by cisplatin
chemotherapy (Hsu et al., 2017), clearly establishing the
GDF15-GFRAL axis as critical to stress pathway-induced
weight loss. Interestingly, two groups also noted that whereas
body weight is similar to that of wild-type littermates in chow-
fed GFRAL null mice, GFRAL null animals gain more weight
on an HFD (Hsu et al., 2017; Mullican and Rangwala, 2018),
whereas the other groups reported similar body weights in
GFRAL null mice on an HFD (Emmerson et al., 2017; Yang
et al., 2017). It is unknown whether circulating levels of
GDF15 rise in response to sustained overfeeding and, if this
occurs, what tisues are responsible.
Here, we explore the relationship betweenGDF15 production
and nutritional state and find that, in contrast to enteroendo-
crine hormones or leptin, GDF15 levels are not influenced by
meals, by the imposition of periods of caloric deficit or caloric
excess of moderate intensity and duration in mice or humans.
However, GDF15 levels do increase significantly when mice
are exposed to chronic high-fat feeding. We then characterize
in detail the elements of the cellular integrated stress response
(ISR) that are involved in the regulation of GDF15 expression
and demonstrate activation of the ISR in selected tissues of
high-fat-fed mice. We also show that another severe nutritional
perturbation, namely provision of a lysine-deficient diet to
mice, activates the ISR and increases GDF15 levels. Finally,
we provide the first evidence that GDF15 generates an aversive
signal through the demonstration of conditioned taste aversion
(CTA) in mice.Figure 1. GDF15 Levels in Response to a Meal or Imposed Caloric Defi
(A–D) Human Study 1 (HS1): (A) plasma glucose, (B) insulin, (C) GLP-1, and (D) GDF
liquidmeal following an overnight fast. Blood sampleswere taken over the 180min
***p < 0.001 compared to time 0 min by one-way ANOVA with Bonferroni post-te
(E–G) Mouse Study 1 (MS1): (E) body weight of mice before and after a 24 h fasting
12-week-old male mice either in the fed state or after a 24 h fast. Data are express
t test. Note all fasted leptin values were under the detection limit (0.033 ng/mL).
(H–J) Human Study 3 (HS3): (H) body weight, (I) leptin, and (J) GDF15 levels in a
(1,000 kcal/day) for a period of 28 days. Data are from 33 participants, expressed
multiple comparison post-test (for body weight and leptin).
(K–M) Human Study 4 (HS4): (K) leptin, (L) b-hydroxybutyrate, and (M) GDF15 le
from 13 participants, expressed as mean ± SEM and analyzed by a one-way ANO
***p < 0.001, ****p < 0.0001 by Kruskal-Wallis test. See also Figures S1 and S4.RESULTS
GDF15 Levels Are Unaffected by Meals or Glucose
Ingestion
It is well established in humans that hormones derived from
enteroendocrine cells respond to acute changes in nutritional
state and play a key role in regulating energy homeostasis. To
determine if GDF15 responds in a similar way, we studied the
response of humans to established stimuli of the enteroendo-
crine system.
In Human Study 1, fasting (overnight) healthy volunteers
received a mixed macronutrient liquid drink (Figures 1A–1D) or
50 g anhydrous glucose (Figures S1A–S1D) followed by 30-min
blood sampling for 180 min. In both studies, glucose peaked at
30 min (6.60 ± 0.26 mmol/L and 8.71 ± 0.16 mmol/L, respec-
tively), with a lower blood glucose in the mixed macronutrient
load reflecting the lower sugar content (22 g) in the test drink.
In parallel with the glucose peak, early increases in both insulin
and GLP-1 levels were observed, whereas circulating GDF15
levels briefly (at 60 min time point) fell after the mixed meal and
were unchanged following glucose ingestion, as reported previ-
ously (Tsai et al., 2015).
GDF15 Levels in Response to an Imposed Caloric Deficit
A fall in the adipose-derived hormone leptin represents an impor-
tant peripheral signal of nutritional deprivation, serving to induce
hyperphagia and suppress selected neuroendocrine hormone
axes. To address the question of whether GDF15 mirrored the
behavior of leptin to changes in nutritional state, we evaluated
the response of circulating GDF15 to fasting and caloric restric-
tion in mice and humans.
First, we examined hormone responses to a 24 h fast in mice
(Mouse Study 1). Despite a 17.8% loss in body weight and a
marked fall in leptin levels, circulating levels of GDF15 were
unchanged (Figures 1E–1G).
Next, circulating GDF15 levels were measured in three inde-
pendent studies in humans subjected to caloric restriction
of varying intensity and duration. In Human Study 2, GDF15
concentrations increased from 319.4 ± 21.27 pg/mL to
406.8 ± 31.24 pg/mL in lean healthy volunteers calorie
restricted for 2 days (10% of estimated daily energy require-
ments) (Figure S1E).
In Human Study 3, a cohort of obese participants consumed
a low-calorie meal replacement diet (1,000 kcal/day) for
28 days. This resulted in a significant reduction in body weightcit in Mice and Humans
15 circulating levels in six healthy volunteers given an oral mixedmacronutrient
duration of the study. Data are expressed asmean ±SEM. *p < 0.05, **p < 0.01,
st.
challenge (n = 5mice). (F) Leptin and (G) GDF15 serum concentrations in 11- to
ed as mean ± SEM (n = 5 mice per group). ***p < 0.001 by two-tailed Student’s
cohort of overweight and obese participants subjected to caloric restriction
asmean ± SEM. *p < 0.05, ****p < 0.0001 by a one-way ANOVAwith Bonferroni
vels in human volunteers subjected to a 7-day fast (0 kcal per day). Data are
VA. In the case of GDF15, values are expressed as median (interquartile range).
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(5.55 ± 2.05 kg from baseline, p < 0.0001; Figure 1H) and leptin
levels (Figure 1I), whereas there was a small, statistically signifi-
cant increase in GDF15 levels (Figure 1J).
In Human Study 4, a group of lean healthy participants under-
went 7 days of total calorie deprivation. As expected, circulating
leptin levels fell precipitously from 6.03 ± 1.18 ng/mL to 2.24 ±
0.49 ng/mL at 24 h (Figure 1K) and amarked ketogenic response
(b-hydroxubutyrate) was observed in response to the fast (Fig-
ure 1L). Meanwhile, circulating GDF15 levels increased, peaking
at 48 h of caloric restriction (from 371.4 ± 94.2 pg/mL at baseline
to 670.2 ± 349.2 pg/mL, p = 0.003). Interestingly, despite contin-
uation of the calorie deprivation, GDF15 levels gradually returned
toward baseline levels, although they remained higher than start-
ing values (441.2 ± 151.3 pg/mL) (Figure 1M).
From these studies in both mice and humans, it is clear that
GDF15 does not exhibit a leptin-like response to caloric restric-
tion. Rather, a small increase in GDF15 levels is observed under
conditions of severe nutritional deprivation.
GDF15 in Response to Short-Term Hypercaloric Loads
In contrast to caloric deprivation, states of nutritional excess and
weight gain are associated with physiological increases in leptin.
We studied the effect of short-term hyper-caloric interventions
on non-obese volunteers to determine if they had a similar effect
on GDF15.
In Human Study 5, we assessed changes in GDF15 in healthy
volunteers in response to short-term high-fat overfeeding. After
7 days of the intervention, a significant increase in body weight
was observed (1.64 ± 1.07 kg, p < 0.0001) compared to baseline
(Figure S1F), accompanied by a significant increase in leptin
levels (Figure S1G). Despite the observed increases in fasting
insulin and glucose levels (Figures S1H and S1I), there was no
significant change in median (IQR) GDF15 levels (302.0 [256.0–
318.0] pg/mL [baseline] versus 295.0 [258.0–343.5] pg/mL [after
overfeeding]) (Figure S1J).
Human Study 6 examined the effect of an 8-week overfeeding
intervention (additional 40% of weight maintenance energy
requirements) on healthy participants in an inpatient setting.
This produced a significant increase in weight (5.52 ± 2.05 kg,
p < 0.0001) and leptin levels (Figures S1K and S1L), but no rise
in circulating GDF15. Indeed, at the end of the intervention,
GDF15 levels were actually lower than at entry to the study
(Figure S1M).
Consistent with these data, GDF15 levels were unchanged
in mice fed an HFD for up to 7 days (Mouse Study 2), despite
the mice manifesting the anticipated increases in fat and liver
weight, and rises in plasma insulin and leptin (Figure S2).
Taken together, these data suggest that, unlike established
hormonal regulators of energy homeostasis, ‘‘modest’’ over-
feeding in humans and mice does not trigger GDF15 production.
GDF15 Levels Are Increased by Sustained
Hypercaloric Loads
As GDF15 is a stress-responsive hormone, we wondered if more
prolonged or severe nutritional stressors might be needed to
induce its expression and secretion. To test this hypothesis,
we undertook a prospective longitudinal study in mice fed either
a CD or HFD from 9 weeks of age (Mouse Study 3). This resulted
in progressive weight gain and fat mass in association with rising710 Cell Metabolism 29, 707–718, March 5, 2019insulin and leptin levels (Figures 2A–2D). Glucose levels were
initially similar in the two groups but rose significantly in the
HFD-fed mice from week 4 onward (Figure 2E). GDF15 levels
started to rise at the 4 week time point and were significantly
higher in the HFD-fed mice from week 8 onward (Figure 2F).
In order to clarify the source of GDF15 in this context, we
analyzed GDF15 mRNA expression in a range of tissues.
GDF15 expression increased in liver, white epididymal adipose
tissue (WAT), and even more strikingly in brown adipose tissue
(BAT), but not in subcutaneous inguinal fat, kidney, and skeletal
muscle (expression was very low in the latter) (Figure 2G).
GDF15 Expression Is Regulated by the Cellular
Integrated Stress Response
Next we sought to establish whyGDF15 expression was induced
in these tissues in this context. Prior work had suggested that
ATF4 and CHOP, key transcriptional regulators of the ISR, might
be involved (Suzuki et al., 2017). The ISR is a cell-autonomous
integrator of diverse cellular stresses, so we began by docu-
menting changes in GDF15 mRNA in mouse embryonic fibro-
blasts (MEFs) treated with a range of well-characterized
stressors (Figure 3). These included cobalt chloride, a chemical
mimic of hypoxia, which acts by stabilizing hypoxia inducible
factor 1a (HIF-1a); unfolded protein response (UPR) inducers
thapsigargin, an inhibitor of sarcoplasmic/endoplasmic reticu-
lum Ca2+-ATPase (SERCA) and tunicamycin, an inhibitor of
N-linked glycosylation, both of which perturb protein folding;
and histidinol, an inhibitor of histidyl tRNA synthetase, which
mimics amino acid deprivation. All these agents caused a signif-
icant and robust induction of GDF15 mRNA expression, albeit to
varying extents, with thapsigargin being the most potent (Fig-
ure 3A). To confirm that GDF15 can be similarly upregulated
in other cell types, we documented stress-induced changes
in GDF15 expression in a range of human cell lines, as well
as in 3T3-L1 preadipocytes (Figures 3B and S3A–S3C). In each
case, GDF15 expression was increased with the level of induc-
tion ranging from 2- to 30-fold.
All of the stress-inducing agents used here can trigger phos-
phorylation of EIF2a by one of four known EIF2a kinases (Har-
ding et al., 2000a, 2000b; Koumenis et al., 2002; Taniuchi
et al., 2016), so we went on to confirm that this did occur at
the concentrations and over the time frames used in our study
(Figure 3C). Indeed, in addition to the stress-induced phosphor-
ylation of EIF2a at Ser51, the protein expression of both the
downstream targets, ATF4 and CHOP, was increased, albeit to
a different extent, with tunicamycin and thapsigargin being the
most potent inducers.
Next, we used a combination of inhibitors and KO or knock-
down MEF lines to test the roles of various elements of the ISR
pathway in the regulation of GDF15. First, using the PERK inhib-
itor GSK2606414 (abbreviated as GSK in Figure 1) or the EIF2a
inhibitor ISRIB (abbreviated as ISR in Figure 1), we demonstrated
that the tunicamycin-mediated induction of GDF15 was signifi-
cantly reduced (Figure 3D), and that this correlated with a reduc-
tion in the activation of the ISR pathway, as judged by decreased
ATF4 and CHOP expression (Figure S3D). We also found that
the tunicamycin-induced expression of GDF15 was abolished
in MEFs harboring a mutation at the key phosphorylation site
on EIF2a (Ser51-Ala) required for ISR activation (Figure 3E).
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Figure 2. GDF15 Is Upregulated by Long-Term High-Fat Feeding in Mice
(A–F) Mouse Study 3 (MS3): C57BL/6J male mice (aged 9 weeks) were fed a chow (CD) or high-fat diet (HFD) for 16 weeks. (A) Body weight was recorded weekly
(CD, n = 7; HFD, n = 8), while (B) fat mass and (C) insulin, (D) leptin, (E) glucose, and (F) GDF15 concentrations were determined at 0, 4, 8, 12 (CD, n = 9–11; HFD,
n = 10–12), and 16 weeks (CD, n = 7; HFD, n = 8) (all after a 4 h fast). Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by
two-way ANOVAwith Bonferronimultiple comparison post-test. The red asterisks in (D) denote time points at which some (1 out of 12 at 12weeks and 3 out of 8 at
16 weeks) leptin values were above the assay detection limit (>100 ng/mL) and thus were set at 100 ng/mL.
(G) GDF15mRNA expression in subcutaneous (SAT), epididymal (EAT), and brown (BAT) adipose tissue, liver, soleus muscle, and kidney isolated fromC57BL/6J
male mice fed a CD or HFD for 18 weeks (n = 6–8 mice/group). mRNA is presented as fold expression (mean ± SEM) relative to the chow-fed state from muscle
(set at 1) and normalized to the geometric mean of B2M/36b4 gene expression. **p < 0.01, ***p < 0.001, ****p < 0.0001 by two-tailed Student’s t test. See also
Figures S2 and S4.Similarly, moving downstream in the pathway, tunicamycin-
induced GDF15 expression was abolished in ATF4 KO MEFs
(Figures 3F and S3E). Furthermore, small interfering RNA
(siRNA)-mediated knockdown of CHOP significantly reduced
both basal and tunicamycin-induced GDF15 expression (Figures
3G and S3F). Coupled with the knowledge that circulating
GDF15 acts via GFRAL in the hindbrain, this establishes
GDF15 as a bona fide systemic endocrine signal of the ISR.
In order to establish if the ISR is indeed responsible for the
observed induction of GDF15 in long-term HF-fed mice, we
next evaluated expression of ATF4 and CHOP mRNA in the
same panel of tissues assessed for GDF15 expression (Mouse
Study 3). These data confirmed that ATF4 and CHOP mRNA
were increased in the liver and BAT (ATF4 only), but interest-
ingly not in WAT (Figures S3G and S3H), suggesting that the
induction of GDF15 in WAT may involve other signaling path-
ways. HF feeding in mice leads to adipocyte cell death, partic-ularly in epididymal fat (Strissel et al., 2007), and this has been
shown to activate macrophages (Cinti et al., 2005). Further-
more, GDF15 was originally identified in activated macro-
phages (Bootcov et al., 1997), so we proceeded to check
mRNA expression of a macrophage marker, F4/80, in the
WAT and BAT samples. F4/80 mRNA increased in parallel
with the changes in GDF15 mRNA (Figure S3I), so we sought
to establish if GDF15 mRNA was being induced in macro-
phages, or other stromovascular fraction (SVF) cells, or in adi-
pocytes themselves. The data suggest that GDF15 mRNA is
induced in both fractions (Figure S3J). However, lipid-laden
macrophages may ‘‘contaminate’’ the adipocyte fraction as
the separation is based on flotation, so we went on to check
for this by analyzing mRNA expression of Plin1 (an adipocyte
marker) and F4/80 in each of the fractions. These data suggest
that macrophages are present in the adipocyte fraction, so it
remains possible that the apparent increase in GDF15 mRNACell Metabolism 29, 707–718, March 5, 2019 711
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Figure 3. GDF15 Expression Is Regulated by the Cellular ISR Pathway
(A and C) GDF15 mRNA expression (A) and immunoblot analysis (C) of ISR components in wild-type (WT) mouse embryonic fibroblasts (MEFs) treated with
vehicle control (Con), cobalt chloride (CoCl2, 625 mM), thapsigargin (Tg, 1 mM), tunicamycin (Tn 5 mg/mL), or L-Histidinol (His, 1 mM) for 6 h.
(B) GDF15 mRNA expression in human cell lines (HeLA, HuH7, and A549) treated with Tn (5 mg/mL) for 6 h.
(D) GDF15 mRNA expression in WT MEFs pre-treated for 1 h either with the PERK inhibitor GSK2606414 (GSK, 200 nM) or eIF2a inhibitor ISRIB (ISR, 100 nM),
then co-treated with Tn (5 mg/mL) for a further 6 h.
(E–G) GDF15mRNA expression (E) in EIF2a Ser51 (SS) or phosphomutant (AA) MEFs or (F) in ATF4 wild-type (WT) or ATF4 knockout (KO) MEFs and (G) in control
siRNA and CHOP siRNA transfected WT MEFs treated with Tn (5 mg/mL) for 6 h.
(H) Diagram outlining pathway by which GDF15 and FGF21 expression is regulated by TN. mRNA expression is presented as fold expression relative to its
respective control treatment for each cell type (set at 1) or TN-treated samples (set as 100) with normalization to HPRT gene expression in MEFs and GAPDH in
human cells.
Data are expressed as mean ± SD from at least three independent experiments. ***p < 0.001 versus control (con) for (A) and (B), and versus TN stimulated for
(D)–(G) by two-tailed Student’s t test. Blots shown are representative of three independent experiments with Calnexin used as a loading control. See also
Figures S3 and S4.is largely coming from macrophages, though we cannot
formally exclude a contribution from adipocytes themselves.
From these data, it is clear that in mice, GDF15 expression is
responsive to chronic conditions of overnutrition that manifest
with changes in GDF15 within adipose tissue (white and brown)
and the liver. These findings are consistent with reported in-
creases in GDF15 levels in ob/ob mice and in obese humans
(Dosta´lova´ et al., 2009; Xiong et al., 2017), though the latter will712 Cell Metabolism 29, 707–718, March 5, 2019require further careful analysis as Tsai et al. (2015) reported
that in non-obese monozygotic twin pairs (n = 72 pairs), the
twin with the higher GDF15 concentration had a lower BMI.
GDF15 Levels in Response to an Amino Acid
Imbalanced Diet
Having demonstrated that nutritional overload can induce
GDF15 expression, we wondered if other nutritional stresses
A B C
D
E F G
H
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Figure 4. GDF15 Is Upregulated in Response to a Lysine-Deficient Diet and Induces Conditioned Taste Aversion in Mice
(A–D) Mouse Study 4 (MS4): (A) GDF15 serum concentrations and (B) ATF4, (C) CHOP, and (D) GDF15 mRNA expression in livers of 11- to 12-week-old female
mice that were fasted overnight and then fed a control chow (Con) or lysine-deficient diet (Lys) for 4 h. A blood sample was withdrawn at 1 h following the
beginning of the meal. Serum and mRNA (4 h time point only) data are expressed as mean ± SEM (n = 6 mice per group) with mRNA normalized to B2M gene
expression. *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA.
(E) Mouse Study 5 (MS5): Circulating plasma GDF15 concentrations after a single dose of recombinant GDF15 in mice; dose response (n = 3/ group).
(legend continued on next page)
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might have similar consequences. Previous studies have shown
that diets deficient in essential amino acids can influence food
intake and increase FGF21 levels in an ATF4-dependent manner
(Gietzen et al., 2016; De Sousa-Coelho et al., 2012, 2013), so we
wondered if such diets might have a comparable impact on
GDF15 levels. This was of particular relevance as we had shown
(Figure 3A) that pharmacological mimics of amino acid imbal-
ance that activate the ISR increase GDF15 expression in cells.
To test this hypothesis, mice were fasted overnight and then
fed a lysine-deficient diet for 4 h (Mouse Study 4). This led to a
marked increase in circulating GDF15 levels compared to
chow-fed animals (Figure 4A). In keeping with activation of the
ISR, ATF4, CHOP, and GDF15 mRNA were all significantly
increased in the livers of these mice (Figures 4B–4D).
GDF15 Administration Results in Conditioned Taste
Aversion
Reduced food intake has been shown to mediate most of the
effects of GDF15 administration or overexpression on body
weight (Emmerson et al., 2017; Macia et al., 2012; Mullican
et al., 2017; Yang et al., 2017). Activation of the GDF15 receptor
(GFRAL) has also been linked to subsequent cFos activation in
the parabrachial nucleus (PBN), which has in turn been linked
to appetite suppression in response to meal-related peptides,
as well as ingestion of toxins, mimicked by lithium chloride and
lipopolysaccharide (Carter et al., 2013; Hsu et al., 2017). Thus,
we hypothesized that GDF15 administration might result in
CTA, which occurs when an animal associates the taste of a nor-
mally favored food with symptoms caused by a concomitantly
administered toxic or aversive substance.
In Mouse Study 5, we first assessed the ability of GDF15 to
lower food intake in a concentration-dependent manner. A single
subcutaneous injection of GDF15 in mice acutely increased
plasma GDF15 concentration, with maximum exposures occur-
ring 1 and 4 h post-treatment (Figure 4E). GDF15 treatment re-
sulted in a corresponding dose-dependent reduction of food
intake that reached statistical significance at the highest dose
(0.1 mg/kg) (Figures 4F and 4G). We then addressed whether
GDF15 induced CTA behavior using the two bottle saccharin
preference test. Similar to the positive CTA control, lithium chlo-
ride, GDF15 treatment at 0.01 mg/kg and 0.1 mg/kg also
reduced saccharin consumption and increased water consump-
tion compared to vehicle control (Figure 4H).
These data demonstrate that acute administration of GDF15
can elicit an aversive response in rodents.
Nutritional Regulation of FGF21 Expression
Although its physiological function in humans is not clearly es-
tablished, FGF21 is another putative systemic signal induced
by the ISR (Fisher and Maratos-Flier, 2016; Salminen et al.,
2017). In humans, plasma FGF21 levels did not change signifi-
cantly following a mixed meal or oral glucose challenge, a
week of total calorie restriction, or high-fat overfeeding in healthy(F andG) Cumulative food intakemeasured between 1 and 4 h post-GDF15 dose e
Data are presented as mean ± SEM. ****p < 0.0001 versus vehicle by one-way A
(H) Saccharin and water consumption during conditioned taste aversion test durin
analyzed using a two-way ANOVA with Bonferroni multiple comparison post-tes
groups of GDF15 or LiCl treatment to vehicle. ****(saccharin) or ####(water) p < 0
714 Cell Metabolism 29, 707–718, March 5, 2019volunteers (Figures S4A–S4D). In mice, short-term overfeeding
induced a small increase in FGF21 levels, whereas prolonged
HFD exposure was associated with a robust increase in FGF21
levels (Figures S4E and S4F). Interestingly, although FGF21
mRNA increased in similar tissues as GDF15, within WAT,
FGF21 seemed to originate from adipocytes themselves rather
than macrophages (Figures S4G and S4H). Lysine-deficient
diet exposure inmice also elicited a significant increase in hepat-
ic FGF21 mRNA (Figure S4I). In cells, FGF21 responses to acti-
vation of the ISR largely mirrored the GDF15 responses with
one notable exception: exaggerated induction rather than
amelioration of the FGF21 response to TN in CHOP knockdown
cells (Figures S4J–S4N). These results suggest that while the ISR
pathway regulates both hormones, the molecular mechanisms
downstream of ATF4 are distinct. These data were corroborated
by the finding that circulating FGF21 and hepatic FGF21 mRNA
levels were significantly increased in mice following a 24 h fast,
despite the lack of a significant change in ATF4 or CHOP
mRNA expression (Figures S4O–S4R). Fasting-induced FGF21
expression is known to involve PPARa (Badman et al., 2007; In-
agaki et al., 2007).
DISCUSSION
Elevating GDF15 levels by transgenic overexpression (Chryso-
vergis et al., 2014; Macia et al., 2012) or pharmacological admin-
istration inmice and nonhuman primates leads to amarked fall in
body weight (Mullican et al., 2017). The principal aim of our work
was to understand if and how GDF15 might be involved in phys-
iological settings of under- and over-nutrition. To this end, we
combined cellular studies with in vivo work in mice and humans
to establish that GDF15 expression is highly responsive to acti-
vation of the ISR in a range of cell types and that its induction
in this setting is dependent upon ATF4 and CHOP. The idea
that cellular stress might be translated into a systemic response
initially emerged from work in C. elegans where an induction of
the mitochondrial unfolded protein response (UPRmt) in neurons
led to changes in mitochondria within physically distinct, non-
innervated tissues (Durieux et al., 2011), but has more recently
been supported by evidence linking FGF21 to the ISR (Salminen
et al., 2017). Chung et al. (2017) also recently proposed that
GDF15 could act as a ‘‘mitohormetic’’ signal of mitochondrial
dysfunction. Our analysis is largely consistent with these data
and provides compelling evidence of the induction of GDF15 in
response to activation of the ISR.
As GDF15 administration causes weight loss and mice lacking
GDF15 are prone to gain weight on an HFD, we determined
whether GDF15 shares any features in common with known
hormonal regulators of post-prandial satiety (e.g., enteroendo-
crine hormones such as GLP-1) or longer term hormonal regula-
tors of nutrient stores (e.g., leptin). In contrast to GLP-1, and
consistent with previous reports (Schernthaner-Reiter et al.,
2016; Tsai et al., 2015), GDF15 did not respond acutely to axpressed as total grams (F) or percent (%) of vehicle control (G) (n = 7–8/group).
NOVA with Bonferroni multiple comparison post-test.
g GDF15 treatment (n = 8–16/group). Data are presented as mean ± SEM and
t to compare proportion of saccharin water and water consumption between
.0001. See also Figure S4.
meal or a glucose load in humans. In mice fasted for 24 h, there
was no change in circulating GDF15, whereas the predicted fall
in leptin levels and rise in FGF21 levels was seen. In humans, 48 h
of severe caloric restriction in lean healthy volunteers resulted in
a significant but small increase in GDF15 concentrations. In
healthy volunteers undergoing a 7 day total fast, GDF15 levels
peaked at around 180% of baseline by day 3 and then pla-
teaued at around 118% at day 7. This early rise in GDF15 is in
the opposite direction expected of a physiological regulator of
energy balance and is more consistent with GDF15 being a
marker of cell/tissue stress. The mechanisms whereby GDF15
levels start to return toward baseline withmore prolonged fasting
are unknown, but presumably reflect some sort of adaptation to
the starved state.
In two separate studies, overfeeding of healthy humans with
an 48% excess of ingested calories for 1 week, or 40% for
8 weeks, did not increase GDF15 concentrations. Of note, in
the longer study, conducted in an inpatient setting, GDF15 levels
showed a small but significant fall (Figure S1M). Among possible
explanations for this fall is the fact that in this inpatient study,
smoking was not permitted. GDF15 levels are known to be posi-
tively associatedwith smoking status and it is possible that some
participants quit smoking just prior to the study (Ho et al., 2012;
Wu et al., 2012).
In contrast to the studies summarized above, we found that
circulating GDF15 levels rose in long-term HF feeding studies
in mice. Whether or not this is also true in humans will require
further studies. As recently summarized by Tsai et al., the rela-
tionship between circulating GDF15 and obesity in humans is
complex. GDF15 levels rise with age and are also induced by
conditions commonly associated with obesity such as diabetes
and cardiovascular disease (Tsai et al., 2018; Wollert et al.,
2017). So while positive correlations between GDF15 and mea-
sures of adiposity have been reported in several small studies
(Dosta´lova´ et al., 2009; Ho et al., 2012; Karczewska-Kupczew-
ska et al., 2012; Kempf et al., 2012; Vila et al., 2011), GDF15
was shown to be inversely correlated with BMI in non-obese
monozygotic twin pairs (Tsai et al., 2015). It is plausible that an
inherent genetically determined increase in GDF15 levels or
one induced by another cell stressor/disease might result in
weight loss, and thus confound straightforward correlations be-
tween BMI and GDF15 levels.
Ravussin et al. have drawn attention to the likely existence of
leptin-independent signals of the obese state that might serve
to restrain the indefinite progression of a state of positive energy
balance and ever increasing obesity (Ravussin et al., 2014). The
fact that mice lacking GDF15 become more obese on an HFD
than wild-type mice suggests that GDF15 might at least
contribute to that signal (Hsu et al., 2017; Tran et al., 2018).
Our studies show that while short-term overfeeding does not in-
crease GDF15, more sustained states of caloric excess will raise
circulating GDF15 levels.
What is the source of the elevated levels of the GDF15 seen in
the overnourished state? In mice, GDF15 mRNA is increased in
liver and BAT, and in certain WAT depots, such as epididymal,
by 18 weeks of HFD, but not in kidney or muscle. In adipose tis-
sue it appears that most of the GDF15 mRNA is likely to be com-
ing from infiltrating macrophages, whereas our initial analyses
suggest that FGF21 mRNA is more robustly induced in adipo-cytes themselves. Macrophages are frequently cited as medi-
ating many of the adverse metabolic consequences of overnutri-
tion such as insulin resistance, through their production of a
range of cytokine-like molecules. In the case of GDF15, it ap-
pears that these cells produce a circulating product that in this
particular context might be beneficial to the organism.
We also show GDF15 is significantly induced by another
nutritional stress, namely a lysine-deficient diet. Interestingly,
involvement of the ISR in response to perturbations affecting
amino acid provision is conserved as far back as yeast (Hinne-
busch, 2005), where the response is clearly cell autonomous.
In metazoans, this response expanded to encompass rectifying
responses to other cell-autonomous perturbations such as the
UPR, hypoxia, viral infections, and iron deficiency (Pakos-
Zebrucka et al., 2016). The link to the GDF15-GFRAL axis sug-
gests that the ISR may now also have gained an endocrine
component potentially involving an aversive response instruct-
ing the animal to change its foraging pattern. In some settings
this is likely to be advantageous to the animal, though there
are clearly exceptions where it is not, such as in cancer cachexia,
where GDF15 levels can be as high as 40,000 pg/mL (Johnen
et al., 2007; Welsh et al., 2003).
What, then, are the consequences of induction of this hor-
mone? GDF15 has been shown to reduce food intake in various
species and to alter food choice. While it has been speculated
that GDF15 may produce an aversive response (O’Rahilly,
2017), this had not previously been formally demonstrated.
Using a CTA paradigm, we show that mice exposed to GDF15
in association with a saccharin taste will avoid saccharin-
containing drinking water in future exposures. CTA is classically
elicited by injection of lithium chloride and is also typical of
agents that are known to produce nausea in humans. In this
context, GDF15 contrasts with leptin, which reduces food intake
but does not produce CTA (Thiele et al., 1997). The lateral PBN,
medial thalamus, and basolateral nucleus of the amygdala are
essential for both acquisition and retention of CTA, with
CGRP-expressing neurons of the PBN playing an essential role
(Palmiter, 2018). Ascending pathways from the AP and NTS
make substantial connections to the lateral PBN. It is therefore
likely, though yet to be formally established, that GFRAL-
expressing neurons of the caudal hindbrain project to the PBN.
In summary, GDF15 appears to be an endocrine signal that
can be produced by almost any cell type in response to activa-
tion of the ISR and presumably other signals. Our data suggest
that ‘‘nutritional stress,’’ whether induced by sustained overnu-
trition as exemplified by prolonged HF feeding in mice or by pro-
vision of an amino acid imbalanced diet, leads to increased
circulating GDF15 levels. We suggest that this might send an
aversive endocrine signal to the brain, though we acknowledge
that further work is needed to verify this hypothesis. If GDF15
is playing a role in restraining progressive weight gain, this sug-
gests that it might have a role in the therapy of obesity. While its
production of CTAmight seem to suggest that it would be poorly
tolerated in humans, it is premature to conclude that this should
prevent its exploration as a possible obesity therapeutic. GLP-1-
based drugs are licensed for the treatment of obesity, yet they
too produce a CTA response in rodents and activate the lateral
PBN (Thiele et al., 1997). With careful titration, most humans
can tolerate therapeutic doses of GLP-1 receptor agonists,Cell Metabolism 29, 707–718, March 5, 2019 715
though nausea and vomiting do lead to its cessation in a signif-
icant number. Thus, these data support the burgeoning interest
in GFRAL, the GDF15 receptor, as an attractive therapeutic
target in so far as it has a highly tissue-specific expression with
actions of GDF15 at sites other than the caudal brain stem seem-
ingly unlikely. Studies of the effects of GDF15 in humans are
eagerly anticipated.
Limitations of Study
Limitations of our studies include the fact that while we have
shown that HF and lysine-deficient diets can induce GDF15,
and that when administered at pharmacological doses, GDF15
can induce an aversive response, we have yet to formally
demonstrate that this also occurs when GDF15 is induced
endogenously. One might also argue that the small increases
in GDF15 we detected in response to extreme fasting in humans
are counter-intuitive; however, we speculate that in these cir-
cumstances, in addition to causing food aversion, GDF15 might
also causemalaise, whichmight encourage an animal to rest and
conserve energy.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Human Study 1: Oral Glucose Tolerance Test (OGTT)/Mixed Meal
The liquid meal test included 12 healthy adult volunteers (3 male/9 female) with a mean ± SD age and BMI of 28 ± 9 years and 23.14 ±
2.74 kg/m2 respectively. Six healthy adult volunteers (4 male/2 female) were recruited to participate in the oral glucose tolerance test
study with mean ± SD age of 30 ± 8 years and BMI of 25.05 ± 3.73 kg/m2. Both studies were completed at the NIHR Wellcome Trust
Clinical Research Facility and the Wellcome-MRC Translational Research Facility, Cambridge Biomedical Campus, UK. Ethical
approval was obtained from the East of England Cambridge South research ethics committee Ref: 16/EE/0338 and the East ofCell Metabolism 29, 707–718.e1–e8, March 5, 2019 e3
England Cambridgeshire and Hertfordshire research ethics committee Ref: 013/EE/0195. Participants provided written consent
prior to participation in the study.
Human Study 2: 48 Hours of Caloric Restriction
14 healthy male volunteers were recruited as participants in the study. The mean ± SD age and BMI of participants was 23.53 ±
2.70 years and 22.08 ± 2.0 kg/m2 respectively. Ethical approval was obtained from the Cambridge local research ethics committee
(Ref: 13EE0107). All participants provided written informed consent before taking part in the study which was completed at the NIHR
Wellcome Trust Clinical Research Facility, Cambridge Biomedical Campus, UK.
Human Study 3: Low Calorie Diet Intervention
50 overweight (BMI > 27 and < 30 kg/m2) or obese (BMI 30-40 kg/m2) participants were enrolled in this study. 33 (3 male and
30 female) were included in this analysis after accounting for withdrawals and insufficient biological samples. Mean ± SD age and
BMI were 38.8 ± 8.8 years and 35.1 ± 3.1 kg/m2 respectively. The study protocol was approved by the Florida Hospital Institutional
Review Board and was carried out in accordance with the Declaration of Helsinki. Clinical trial number: NCT01616082 (https://
clinicaltrials.gov). Before taking part in the study, all participants were evaluated for eligibility. All participants provided their written
consent to take part in the study.
Human Study 4: Calorie Restriction
In total 13 healthy adult participants (7 male/6 female) were recruited to the study. The inclusion criteria for participation were age
18-45 years, percent body fat from DEXA > 12% for males and > 15% for females. Mean ± SD age of participants was 29.7 ± 6.1
years and BMI was 25.04 ± 3.32 kg/m2. The study protocol was initially reviewed by the Regional Ethics Committee of Norway
(2017/1052; REK sør-øst B) with the decision that the research project was outside the Act on Medical Health Research, confirmed
in a letter of exemption (2017/1052b). The study was then approved by the Ethics Committee at the Norwegian School of Sport
Sciences (15-220817). The study was undertaken at the Norwegian School of Sports Sciences, Oslo, Norway. Written consent
was obtained from volunteers prior to participation in the study.
Human Study 5: 7 Day High Fat Diet Overfeeding
A total of 28 adult participants (25 males/3 females) were included in the study. Mean ± SD age and BMI of the study cohort were
22.6 ± 3.7 years and 24.2 ± 2.5 kg/m2 respectively. Subjects were physically active (taking part in at least 3 3 30 min of moder-
ate-intensity physical activity each week), non-smokers, with no diagnosis of cardiovascular or metabolic disease, not taking any
medication, and body mass was stable for at least 3 months. Both studies were approved by the Loughborough University Ethical
Subcommittee for Human Participants (R13-P171 and R16-P132). All participants gave written consent to take part after the
experimental procedures.
Human Study 6: 8 Week Overfeeding
20 healthy adult volunteers (11 male /9 female) with a mean ± SD age and BMI of 24.3 ± 4.3 years and 25.2 ± 3.0 kg/m2 respectively
who led a sedentary lifestyle (less than 2 h of moderate to vigorous exercise per week) were recruited to an 8week overfeeding study.
Written consent approved by the Pennington Biomedical Research Center Institutional Review Board was provided by all partici-
pants. This trial was registered at clinicaltrials.gov (number NCT00565149). The study was undertaken at the Pennington Biomedical
Research Center (Baton Rouge, Louisiana, USA).
Mouse Studies
Mouse Study 1: Fed/Fast Study
Ten C57BL/6J mice were purchased from Charles River (Charles River Ltd, Manston Rd, Margate, Kent, CT9 4LT) at 7-8 weeks of
age. Mice were maintained in open vented cages with group housing (2 or 3 per cage) in a 12 h light/12 h dark cycle (lights on
07:00–19:00), temperature-controlled (22C) facility, with ad libitum access to food and water. This research was regulated under
the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge
Animal Welfare and Ethical Review Body (AWERB).
Mouse Study 2 and 3: Short- and Long- Term High Fat Diet Studies
C57BL/6J mice were purchased from Charles River (Charles River Ltd, Manston Rd, Margate, Kent, CT9 4LT) or bred in-house for
some long-term HFD experiments. Mice were maintained in ventilated cages with group housing (2 or 3 per cage) in a 12 h light/12 h
dark cycle (lights on 06:00–18:00), temperature-controlled (20-24C) facility, with ad libitum access to food and water. All mice were
fed either ad libitum or as stated otherwise prior to harvesting tissue and serum analysis. This research was regulated under the
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge
Animal Welfare and Ethical Review Body (AWERB).
Mouse Study 4: Lysine Nutritional Deficiency Experiment
Mice were originally purchased at Janvier Labs (Route du Genest, 53940 Le Genest-Saint-Isle, France) and bred in-house. All mice
were maintained in standard housing conditions (22C) on a 12 h light-dark cycle (lights on 08:00-20:00). Animal experiments were
carried out in accordance with INRA guidelines in compliance with European animal welfare regulation. Mouse maintenance and all
experiments have been approved by the institutional animal care and use committee, in conformance with French and European
Union laws (permission to experiment on mice #5558, animal facilities agreement D6334515, GMO agreement #4713).
For the lysine nutritional deficiency experiment, an experimental diet was manufactured in the INRA diets core facility
(Unite´ de Pre´paration des Aliments Expe´rimentaux, INRA) and nutritional experiments were performed as previously describede4 Cell Metabolism 29, 707–718.e1–e8, March 5, 2019
(Chaveroux et al., 2016; Maurin et al., 2005). Briefly, the nutritional deficiency in an essential amino acid is carried out by means of
experimental diets in which the protein fraction is replaced by a mixture of free amino acids.
Mouse Study 5: Conditioned Taste Aversion (CTA) Test
Male C57BL/6N mice were obtained from Taconic Farms (25-30 g). All mice were maintained in standard housing conditions
(21-24C; 45% humidity) on a 12 h light-dark cycle (lights on 06:00, lights off 18:00). Mice were singly housed in the BioDAQ caging
system (Research Diets, New Brunswick, NJ, USA) and allowed ad libitum access to tap water and standard rodent chow (Purina
5053) unless otherwise noted. All procedures were approved by the Pfizer-Massachusetts Animal Care and Use Committee.
Eukaryotic Cell Lines
Mouse embryonic fibroblast (MEF) cells lines were obtained from David Ron (CIMR/IMS, Cambridge) and maintained in Dulbecco’s
Modified Eagle’s Medium supplemented with 10% (vol/vol) fetal bovine serum (FBS), 2 mM L-glutamine, penicillin/streptomycin, 1%
Sodium Pyruvate, 1% Non-Essential Amino Acids and 2-Mercaptoethanol. HeLa (human cervical carcinoma obtained from ATCC),
HuH7 (human hepatocarcinoma obtained from Albert Pol, IDIBAPS, Barcelona), A549 (human lung epithelial carcinoma obtained
from ATCC) were cultured in the samemedia asMEFs but without 2-Mercaptoethanol. 3T3-L1 preadipocytes (obtained from Zenbio)
cells were cultured in complete DMEM containing 10% newborn calf serum (NCS), 2 mM L-Glutamine, Penicillin-Streptomycin, 1%
Non-Essential Amino Acids and 1% Sodium Pyruvate. All cells were maintained at 37C in a humidified atmosphere of 5% CO2
METHOD DETAILS
Human Studies
Human Study 1: Oral Glucose Tolerance Test (OGTT)/Mixed Meal
On the day before the assessment all participants received a standardized evening meal at 18:00, before commencing an overnight
fast. The energy content of the meal was one third of a participant’s daily requirements estimated from predicted resting metabolic
rate and multiplied by an activity factor of 1.35 (Schofield, 1985; Westerterp, 1999). Meal composition consisted of 30%–35% fat,
12%–15% protein and 50%–55% carbohydrate by energy. Anthropometric measurements were acquired for all participants on
arrival to the clinical research facility. Participants were cannulated prior to administration of an oral liquid meal consisting of a
200 mL Ensure Plus (Total energy 330 kcal; Protein 16.7%, Carbohydrate 53.8%, Fat 29.5%) or a glucose drink (50 g anhydrous
glucose in 200 mL water) with these particular participants described in Roberts et al. (2018). Blood samples were taken at
30 min intervals over the 180 min duration of the study. EDTA and Lithium heparin samples were placed immediately on ice while
serum samples remained at room temperature for 30 min prior to centrifugation at 4C at 3500 rpm for 10 min, plasma was frozen
on dry ice and stored at 70C until the time of biochemical analysis. Assays were completed by the Cambridge Biochemical Assay
Laboratory, University of Cambridge. SerumGDF15measurements were undertakenwith antibodies & standards fromR&DSystems
(R&D Systems Europe, Abingdon UK) using a microtiter plate-based two-site electrochemiluminescence immunoassay using the
MesoScale Discovery assay platform (MSD, Rockville, Maryland, USA). Plasma glucose was determined using a hexokinase assay
on a Siemens Dimension ExL Analyzer. Plasma insulin measurements using the Diasorin Liaison XL automated onestep chemilumi-
nesence immunoassay (Diasorin S.p.A, 13040 Saluggia (VC), Italy). Plasma total GLP-1wasmeasured bymicrotiter plate-based two-
site electrochemiluminescence immunoassay using a Meso Scale Discovery kit (Gaithersburg, MD, USA). FGF21 levels were
measured in duplicate on serum samples using the human FGF21 Quantikine ELISA kit (R&D Systems).
Human Study 2: 48 Hours of Caloric Restriction
Study volunteers attended the clinical research facility after an overnight fast. During the study, participants were required to eat all of
the meals provided by the research team. For the first 24 h of the study (day 1), all of the meals provided to participants contained
100%of their estimated daily energy requirements based on the Scholfield equation andwere composed of 50%carbohydrate, 30%
fat and 20% protein (Schofield, 1985). Baseline blood tests were acquired upon waking on day 2 of the study. For the following 48 h
(day 2 and 3) participants were calorie restricted to meals containing 10% of their daily estimated energy requirements. Blood
samplingwas repeated uponwaking on day 4 of the study protocol, prior to refeeding. Serum samples remained at room temperature
for 30 min prior to centrifugation at 4C at 3500 rpm for 10 min, plasma was frozen on dry ice and stored at 80C until the time of
biochemical analysis. Assays were completed by the Cambridge Biochemical Assay Laboratory, University of Cambridge. Serum
GDF15 measurement were undertaken with antibodies & standards from R&D Systems (R&D Systems Europe, Abingdon UK) using
a microtiter plate-based two-site electrochemiluminescence immunoassay using the MesoScale Discovery assay platform (MSD,
Rockville, Maryland, USA).
Human Study 3: Low Calorie Diet Intervention
At day 0, prior to initiation of the low-calorie dietary (LCD) intervention, baseline fasting blood sampling and anthropometry were
measured. Participants were provided with dietary counselling and meal-replacement shakes at this and subsequent visits, and
the LCD was initiated. Participants received a low-calorie diet for 8 weeks at approximately 1000 kcal per day, replacing 2 meals
with approximately 600 kcal of meal replacement shakes followed by a dinner of approximately 400 kcal. Dinners were chosen
from an approved list of Lean Cuisine and Healthy Choice brand meals. Participants were free living for the duration of the study
and attended at days 14 and 28 of the intervention for assessment where blood sampling and anthropometric measures were
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EDTA plasma samples underwent centrifugation at 4C, 4000 rpm for 15 min and stored at 80C until analysis. Biochemical
assays were undertaken at the Translational Research Institute for Metabolism and Diabetes (Florida Hospital). Plasma GDF15
wasmeasured using antibodies & standards from R&D Systems (R&D Systems Europe, Abingdon UK) using amicrotiter plate-based
two-site electrochemiluminescence immunoassay using the MesoScale Discovery assay platform (MSD, Rockville, Maryland, USA).
Plasma leptin was assayed using the MesoScale Discovery platform, (Human Leptin).
Human Study 4: Calorie Restriction
Participants were free living for the duration of the caloric restriction. Anthropometric measurements were acquired at baseline and at
the end of the study. On day 0 all participants had a breakfast meal ad libitum prior to commencing the caloric restriction to 0 kcal per
day for a total of 7 days. Water was permitted throughout the study. During the study, weight (mean ± SD) fell from 79.6 ± 5.0 kg at
baseline to 73.8 ± 4.8 kg after 1 week of fasting. The measurements of mean ± SD body fat were acquired by dual-energy X-ray ab-
sorptiometry (DEXA) and are reported as an average of twomeasurements at baseline on day1 and 0 (18.6 ± 1.8 kg) or following the
fast on days 6 and 7 (17.3 ± 1.9 kg). Participants attended the research facility each morning for phlebotomy where both serum and
plasma (EDTA and Lithium Heparin) samples were acquired. Plasma samples were immediately placed on ice while serum samples
remained at room temperature for 30min to coagulate prior to centrifugation at 4Cat 3500 rpm for 10min. Samples were then imme-
diately frozen on dry ice and stored at 80C until the time of biochemical analysis. Plasma Leptin and GDF15 measurements were
undertaken at the Cambridge Biochemical Assay Laboratory, University of Cambridge using antibodies & standards from R&D
Systems (R&D Systems Europe, Abingdon UK). A two-site microtiter plate-based Delfia assay measured Leptin. GDF15 was
measured using a microtiter plate-based two-site electrochemiluminescence immunoassay using the MesoScale Discovery assay
platform (MSD, Rockville, Maryland, USA). The analytic processes of b-Hydroxybutyrate were conducted according to the manufac-
turer’s instructions. Plasma concentration of b-Hydroxybutyrate (mmol/l) were undertaken at the Department of Clinical Medicine,
Diabetes and Hormone Diseases - Medical Research Laboratory, Aarhus University, Denmark using a kinetic enzymatic method,
based on the oxidation of D-3-hydroxybytyrate to acetoacetate by the enzyme 3-Hydroxybutyrate dehydrogenase (Randox Labo-
ratories Ltd., Crumlin, UK) and measured on the Cobas c111 system (Roche Diagnostics International Ltd, Rotkreuz, Switzerland).
FGF21 levels were measured in duplicate on serum samples using the human FGF21 Quantikine ELISA kit (R&D Systems).
Human Study 5: 7 Day High Fat Diet Overfeeding
Prior to the start of the study, subjects attended the research facility at Loughborough University for an initial assessment of their
baseline anthropometric characteristics. This informationwas then used to estimate resting energy expenditure (REE) using validated
equations (Mifflin et al., 1990). A standard correction for physical activity (1.6 and 1.7 times REE for females and males, respectively)
was applied in order to estimate total daily energy requirements. This information was then used to determine individual energy in-
takes for the overfeeding period. Experimental trials were conducted immediately before and after 7 days of high-fat overfeeding.
Briefly, subjects arrived at the laboratory in themorning (07:00-09:00) after an overnight fast (R10 h), having refrained from strenuous
exercise for 48 h and having avoiding alcohol or caffeine intake for 24 h. Bodymasswas recorded after subjects had voided. A venous
blood sample was then obtained after 30 min of seated rest. Blood samples were collected for plasma (EDTA) or serum. Blood
samples were then centrifuged, and the resulting plasma / serum stored at 20C until analysis. Upon completion of the first exper-
imental trial, subjects were provided with all food to be consumed for the following 7 days. The high-fat diet provided 19974 ± 474 kJ
per day (48 ± 1%greater than estimated daily requirement), with 178 ± 5 g [15%] protein, 245 ± 5 g [21%] carbohydrate, and 342 ± 9 g
[64%] fat intake. Diet compliance was assessed by daily interview. Plasma glucose concentration was determined using a spectro-
photometric assay (Glucose PAP; Horiba Medical, Northampton, UK) and semi-automatic analyzer (Pentra 400; Horiba Medical,
Northampton, UK). Serum insulin concentration was determined by ELISA (EIA-2935; DRG Instruments GmBH, Marburg, Germany).
Serum Leptin andGDF15measurements were undertaken at theCambridge Biochemical Assay Laboratory, University of Cambridge
using antibodies & standards from R&D Systems (R&D Systems Europe, Abingdon UK). A two-site microtiter plate-based Delfia
assay was used to measure Leptin. GDF15 was measured using a microtiter plate-based two-site electrochemiluminescence
immunoassay using the MesoScale Discovery assay platform (MSD, Rockville, Maryland, USA). FGF21 levels were measured in
duplicate on serum samples using the human FGF21 Quantikine ELISA kit (R&D Systems).
Human Study 6: 8-Week Overfeeding
Details of this study were previously described (Bray et al., 2012, 2015). Briefly, this was a randomized, parallel-arm, in-patient
study. Participants remained in-patients at the Biomedical Research Center for approximately 12 weeks without leaving. The first
13–25 days of the in-patient stay (Baseline) were used to establish energy requirements for weight maintenance. The baseline
diet consisted of 361 g of carbohydrates, 67 g of fat, 90 g protein for a total of 2412 kcal. Once weight stability was achieved, baseline
assessments were performed, including blood draws and measurements of body composition by dual-energy X-ray absorptiometry
(DEXA). Overfeeding was planned at approximately 40% above energy requirements for weight maintenance or approximately
1000 kcal/d (4180 kJ/d). During the final 24 h period, the diet was returned to the baseline components and the same baseline
assessments were performed at the end of the 8 week overfeeding. Participants ate all food provided during the study period.
Plasma glucose was measured using a glucose oxidase electrode (DXC 600 Pro; Beckman Coulter), and insulin was measured
by an immunoassay (Immulite 2000; Siemens). Plasma free fatty acids (FFAs) weremeasured with a high-sensitivityWako kit. Plasma
GDF15 measurements were undertaken with antibodies & standards from R&D Systems (R&D Systems Europe, Abingdon UK)
using a microtiter plate-based two-site electrochemiluminescence immunoassay using the MesoScale Discovery assay platform
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Mouse Studies
Mouse Study 1: Fed/Fast Study
When aged 11-12 weeks old, on day 1 of the study the mice were divided into two groups of five mice, either ‘‘fed’’ or ‘‘fasted.’’ The
body weight of the two groups at study start were matched (fed versus fast, mean ± SEM; 27.68 ± 0.45 g versus 27.70 ± 0.59 g). At
09:00, mice were transferred into clean cages in the same grouped arrangement as during the maintenance period. Home cage
bedding was also transferred into clean cages to reduce stress. Animals in the ‘‘fasted’’ group had all food removed, animals in
the ‘‘fed’’ had ad libitum access to food. All animals had free access to water. 24 h later (09:00 on day 2 of study) mice were weighed
then received a terminal dose of anesthetic (Dolethal 200 mg/mL solution, Vetoquinol UK Ltd.) given via the intraperitoneal route.
Once unresponsive, blood was collected by cardiac puncture, transferred into a Microtube 1.1 mL Z-Gel (Sarstedt AG & Co) and
spun at 10 000 x g for 5 min at room temperature. Serum was collected, frozen on dry ice and stored at 80C until analyzed. After
cardiac puncture, body composition wasmeasured using DEXAwith a Lunar PIXImusMouse Densitometer (GEHealthcare Systems)
and tissue was harvested, frozen on dry ice and stored at 80C until being processed.
Mouse Study 2 and 3: Short- and Long- Term High Fat Diet Studies
For the short-term high fat diet study (Mouse Study 2), 17-18 week old mice were fed a 45% high-fat diet (D12451i, 45% kcal as fat,
4.7 kcal/g, Research Diets) for 1, 3 or 7 days. A separate control group was kept on a chow diet (Safe Diets, DS-105). On the morning
(10:00) of the specified days, mice were weighed and blood collected by cardiac puncture into microtubes containing serum gel with
clotting activator and centrifuged at 13 000 rpm for 10 min at 4C and stored at 80C for serum GDF15 and insulin measurements.
Mouse glucose levels weremeasured from approximately 2 ml blood drops using a glucometer (AlphaTrak2; Abbot Laboratories) and
glucose strips (AlphaTrak2 test 2 strips, Abbot Laboratories, Zoetis). Tissues were harvested and weighed.
For the long-term chronic high fat diet study (Mouse Study 3), 9 week-old malemice were subjected to either a chow or high fat diet
(as in short-termHFD) over a period of 18weeks. All micewereweighedweekly and body compositionwas determined every 4weeks
by Time-Domain Nuclear Magnetic Resonance (TD-NMR) using a Minispec Live Mice Analyzer (LF50, Bruker). Tail blood samples
were collected into heparinizedmicro blood tubes (01605-00, Hawksley), centrifuged at 13,000 x g for 4min for plasmaGDF15, leptin
and insulin measurement. Mouse glucose levels were measured as described above in the short-term HFD study. At the end of the
experiment, mice were fasted for 4 h and tissue was harvested and stored at 80C. For isolating stromo-vascular and adipocyte
fractions, epididymal adipose tissue was minced into small pieces and resuspended in 5 mL Hanks’ Balanced Salt Solution (Sigma)
containing collagenase Type I (Sigma). The tissue was completely disaggregated by incubation in a 37C shaker for approximately
10 min. The digested material was filtered through a 100 mm nylon mesh cell strainer, and 10 mL of 10% FBS DMEM added. After a
5-10min incubation at room temperature, the upper phase containing the adipocytes was transferred into a new tube. The remaining
supernatant was centrifuged at 700 x g for 10min and the pellet containing the stromo- vascular fractionwas collected. Both fractions
were frozen at 80C until further analysis.
Mouse Study 4: Lysine Nutritional Deficiency Experiment
Eighteen 10week old C57BL/6J femalemicewere habituated to the control experimental diet (containing 20 free amino acids) for one
week. The night before the experiment, mice were fasted for 16 h before offering them a control meal or a meal lacking lysine. Mice
were divided into three groups of six mice: the first group was fasted overnight; the second group was fasted overnight, then fed the
control diet; the third group was fasted overnight, then fed the lysine devoid diet. A blood sample was collected from fed mice at 1 h
after the beginning of the meal by sub-mandibular sampling. At the time of sacrifice (4 h after the beginning of the meal for fed mice),
the blood of all mice was withdrawn by cardiac puncture and treated with EDTA (500mM) along with the tissues being harvested and
stored at 80C for analysis.
Mouse Study 5: Conditioned Taste Aversion (CTA) Test
Human recombinant GDF15 (Peprotech) was prepared in saline, which was used as the vehicle control. GDF15 was administered via
subcutaneous (SC) injection as a single dose in all mouse studies. LiCl (Sigma) was also prepared in saline and administered via SC
injection as a single dose in all mouse studies. Mice were acclimated (up to 3 days) to drinking from two water bottles to confirm lack
of side preference prior to habituation. Micewere then habituated to overnight water restriction (days 1-3) followed by 1 hwater bottle
presentation (two bottles) and saline SC injection. On day 4 to begin conditioning, mice were instead given a novel 0.15% saccharin
solution in both bottles instead of water for 1 h, followed by a SC injection of either saline, GDF15 (within the dose range that induces
anorexia) or the positive control LiCl. Access to saccharin water was allowed for an additional 30 min and was then changed back to
water until the next restriction. Day 5 was used as a GDF15 washout period using the days 1-3 bottle protocol. A second conditioning
period was performed on day 6 followed by a washout period on day 7. On day 8, a standard two bottle preference test (saccharin
versus water) was used to assess CTA development to the saccharin solution (1 h presentation after overnight water restriction). The
CTA test was performed 48 hours after the last GDF15 injection, and volumemeasurements were for 1 hour. Fluid intake volume was
calculated for both saccharin and water. The total volume drunk in saline group was 1.4 mL and there was no statistical differences in
the treatment groups. Foodweight wasmeasuredmanually using a digital scale. Foodweight wasmeasured at 1 h and 4 h following a
single injection of GDF15 given immediately prior to the onset of the dark cycle. A separate group ofmicewas used for plasmaGDF15
pharmacokinetic analysis. Bloodwas collected at 0.25 h, 1 h, 4 h, 8 h, and 24 h after GDF15 injection in EDTA tubes containing AEBSF
and aprotinin, and then centrifuged (10 000 rpm; 10 min) for plasma separation all at 4C and then stored at 80C. Plasma human
GDF15 was measured using the human GDF15 Quantikine ELISA kit per manufacturer instructions.Cell Metabolism 29, 707–718.e1–e8, March 5, 2019 e7
Eukaryotic Cell Lines
Cells were seeded onto 6- or 12-well plates prior to stress treatments the following day for the times and concentrations indicated.
Vehicle treatments (e.g., DMSO or ethanol) were used for control cells when appropriate.
siRNA Transfection and Knockdown CHOP
Wild-type MEFs were seeded onto 12-well plates and transfected with 30 nM control siRNA or siRNA for mouse CHOP using
Lipofectamine RNAi MAX (Invitrogen) according to the manufacturer’s instruction. 48 h post siRNA transfection, cells were treated
with ISR stressors for 6 h and subsequently processed for RNA and protein expression analysis.
RNA Isolation/cDNA Synthesis/Q-PCR
Following treatments, cells were lysed with Buffer RLT (QIAGEN) containing 1% 2-Mercaptoethanol and processed through a Qiash-
redder with total RNA extracted using the RNeasy isolation kit according to manufacturer’s instructions (QIAGEN). Meanwhile for
mice, tissues were harvested and immediately snap frozen in liquid nitrogen and stored at80C until further analysis. For RNA isola-
tion, approximately 30-50mg of tissue was placed in LysingMatrix D tubes and homogenized in 800 ml Triazol (Qiazol,QIAGEN) using
the Fastprep-24 Homogenizer for 30 s at 4-6 m/s (MP Biomedical), or a rotor-stator homogenizer. The resultant supernatant was
transferred to an RNase free tube and 200 ml chloroform (Sigma) added. The samples were vortexed and centrifuged at 13
000 rpm for 15 min at 4C. The upper phase was then transferred to a RNase free tube and mixed with equal volume of 70% ethanol
before loading onto RNA isolation spin columns (QIAGEN). RNA was then extracted (and in some instances treated with DNase1
on-column) using the RNeasy isolation kit following the manufacturer’s instructions.
RNA concentration and quality was determined by Nanodrop. 400 ng - 500 ng of total RNA was treated with DNAase1
(Thermofisher Scientific) and then converted to cDNA using MMLV Reverse Transcriptase with random primers (Promega). Quanti-
tative RT-PCR was carried out with either TaqMan Universal PCR Master Mix or SYBR Green PCR master mix on the QuantStudio 7
Flex Real time PCR system (Applied Biosystems). All reactions were carried out in either duplicate or triplicate and Ct values were
obtained. Relative differences in the gene expression were normalized to expression levels of housekeeping genes, HPRT or GAPDH
for cell analysis and to B2M and 36b4 geometrical mean for mouse data, using the standard curve method. Primer sequences are
shown in the Key Resources Table.
Serum and Media Analysis
Tail blood samples from random fed or 4 h fasted (for the long term HFD study) mice were collected for serum analysis. Mouse leptin
and insulinweremeasured simultaneously using a 2-plexMouseMetabolic immunoassay kit fromMesoScaleDiscoveryKit (Rockville,
MD, USA). The assay was performed according to the manufacturer’s instructions and using calibrators provided by MSD. Mouse
GDF15 was measured using a Mouse GDF15 DuoSet ELISA (R&D Systems) which had been modified to run as an electrochemilumi-
nescence assay on the Meso Scale Discovery assay platform. Mouse FGF21 was analyzed by FGF21 Quantakine ELISA (R&D Sys-
tems) following themanufacturer’s instructions.Mouse samplemeasurementswere performedby theMRCMDUMouseBiochemistry
Laboratory [MRC_MC_UU_12012/5]. For the human studies, the details of the serum/plasma analysis performed are described sepa-
rately for each study (see Method Details section of each study above). All FGF21 measurements were completed by the Cambridge
Biochemical Assay Laboratory, University of Cambridge using the human FGF21 Quantikine ELISA kit (R&D Systems).
Immunoblotting
Following treatments, cells were washed twice with ice cold D-PBS and proteins harvested using RIPA buffer supplemented with
cOmplete protease and PhosStop inhibitors (Sigma). The lysates were cleared by centrifugation at 13 000 rpm for 15 min at 4C,
and protein concentration determined by a Bio-Rad DC protein assay. Typically, 20-30 mg of protein lysates were denatured in
NuPAGE 4 3 LDS sample buffer and resolved on NuPage 4%–12% Bis-Tris gels (Invitrogen) and the proteins transferred by iBlot
(Invitrogen) onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk or 5% BSA for 1 h at room tem-
perature and incubated with the antibodies described in the STARMethods table. Following a 16 h incubation at 4C, all membranes
were washed five times in Tris-buffered saline-0.1% Tween-20 prior to incubation with horseradish peroxidase (HRP)-conjugated
anti-rabbit immunoglobulin G (IgG), HRP-conjugated anti-mouse IgG. The bands were visualized using Immobilon Western Chemi-
luminescent HRP Substrate (Millipore). All images were acquired on the ImageQuant LAS 4000 (GE Healthcare).
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantitative data are reported asmean ± SD for cells andmean ± SEM for mouse data. As indicated in the figure legends, differences
between means were assessed by two-tailed Student’s t tests or One-way ANOVA or Two-way ANOVA with Bonferroni multiple
comparisons test using either GraphPad Prism software (GraphPad, San Diego) or with SAS version 9.4, Cary, N. Carolina. Statistical
significance was defined as p < 0.05.
Data from human studies was analyzed using GraphPad Prism software (GraphPad, San Diego). Parametric quantitative data is
expressed as mean ± SEM and the difference in the mean was assessed using a Two tailed Student’s t test. In the case of non-para-
metric data, it is reported asmedian (interquartile range) and compared using aWilcoxon signed rank, Kruskal-Wallis orMannWhitney
test. Details of specific analyses are reported in the respective figure legends. Statistical significance was defined as p < 0.05.e8 Cell Metabolism 29, 707–718.e1–e8, March 5, 2019
